Gibson Oncology, anti-cancer agents

Website being updated with our information on Gibson Oncology’s exciting and important new developments that include:

  1. Orphan Drug Designation (ODD) from the FDA for both Glioblastoma and multiple types of Gliomas.
  2. Ongoing discussions with the NIH on conducting Phase II Clinical Trials in GBM.
  3. Agreement with a major pharmaceutical company regarding their support and participation in our Phase II Clinical Trials.

Gibson Oncology will release more specific information when granted permission from our partners. 

Mark C. Rogers, M.D., M.B.A.

Executive Chair

Randall Riggs

President and CEO